Risk and Benefit of CD133+ Progenitors
July 2009
in “
Circulation Research
”
Studysummary This article discusses the potential therapeutic use of CD133+ progenitor cells and their conditioned medium for diabetic ischemic ulcers, reporting no new results.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ahajournals.org →